The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds

International Journal for Parasitology

Volumn 34, Issue 4, 2004, Pages 433-444

  Gumy, Alain ^a   Louis, Jacques A ^a,b   Launois, Pascal ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b INSTITUT PASTEUR   (France)

Author keywords

Cytokines; Infection with Leishmania; Th1 Th2 responses

Indexed keywords

CYTOKINE;

PARASITOLOGY;

BIOACCUMULATION; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DISEASE COURSE; GENETIC DIFFERENCE; GENETIC RESISTANCE; IMMUNE RESPONSE; IN VIVO STUDY; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PATHOGENESIS; POLARIZATION; REVIEW; T LYMPHOCYTE; TH2 CELL;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; SPECIES SPECIFICITY; TH1 CELLS; TH2 CELLS;

LEISHMANIA MAJOR; MAMMALIA; MURINAE; PROTOZOA;

EID: 1542298831     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2003.11.021     Document Type: Review

References (123)

1. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
2. + T cells. Nat. Immunol. 3:2002;549-557.
3. Ahn H.-J., Maruo S., Tomura M., Mu J., Hamaoka T., Nakanishi K., Clark S., Kurimoto M., Okamura H., Fujiwara H. A mechanism underlying synergy between IL-12 and IFN-γ Inducing Factor in enhanced production of IFN-γ J. Immunol. 159:1997;2125-2131.
4. + T cells. J. Immunol. 169:2002;3232-3241.
5. Assreuy J., Cunha F.Q., Epperlein M., Noronha-Dutra A., O'Donnell C.A., Liew F.Y., Moncada S. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur. J. Immunol. 24:1994;672-676.
6. Bagley J., Sawada T., Wu Y., Iacomini J. A critical role for interleukin 4 in activating alloreactive CD4 T cells. Nat. Immunol. 1:2000;257-261.
7. Barral-Netto M., Barral A., Brownell C.E., Skeiky Y.A.W., Ellingsworth L.R., Twardzik D.R., Reed S.G. Transforming growth factor-β in leishmanial infection: a parasite escape mechanism. Science. 257:1992;545-548.
8. Beebe A., Mauze S., Schork N.J., Coffman R.L. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Immunity. 6:1997;551-557.
9. Behin R., Maüel J., Sordat B. Leishmania tropica: pathogenicity and in vitro macrophage function of inbred mice. Exp. Parasitol. 48:1979;81-91.
10. Belkaid Y., Hoffmann K.F., Mendez S., Kamhawi S., Udey M.C., Wynn T.A., Sacks D.L. The role of interleukin(IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194:2001;1497-1506.
11. + regulatory T cells control Leishmania major persistence and immunity. Nature. 420:2002;502-507.
12. Belosevic M., Finbloom D.S., van der Meide P.H., Slayter M.V., Nacy C.A. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:1989;266-274.
13. Biedermann T., Zimmermann S., Himmelrich H., Gumy A., Egeter O., Sakrauski A.K., Seemüller I., Voigt H., Launois P., Levine A.D., Wagner H., Heeg K., Louis J.A., Rocken M. IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2:2001;1054-1060.
14. Bird J.J., Brown D.R., Mullen A.C., Moskowitz N.H., Mahowald M.A., Sider J.R., Gajewski T.F., Wang C.-R., Reiner S.L. Helper T cell differentiation is controlled by cell cycle. Immunity. 9:1998;229-237.
15. Campbell K.A., Ovendale P.J., Kennedy M.K., Fanslow W.C., Reed S.G., Maliszewski C.R. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity. 4:1996;283-289.
16. Chatelain R., Mauze S., Coffman R. Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol. 21:1999;211-218.
17. Chen Q., Ghilardi N., Wang H., Baker T., Xie M.-H., Grewald I.S., de Sauvage F.J. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature. 407:2000;916-920.
18. Cherwinski H.M., Schumacher J.H., Brown K.D., Mosmann T.R. Two types of mouse helper T cell clones. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J. Exp. Med. 166:1987;1229-1244.
19. Chomarat P., Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int. Rev. Immunol. 17:1998;1-52.
20. Conceiçao-Silva F., Hahne M., Schröter M., Louis J., Tschopp J. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicyty. Eur. J. Immunol. 28:1998;237-245.
21. Corry D.B., Reiner S.L., Linsley P.S., Locksley R.M. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153:1994;4142-4148.
22. Ebner S., Ratzinger G., Krosbacher B., Schmuth M., Weiss A., Reider D., Krockzek R.A., Herold M., Heufler C., Fritsch P., Romani N. Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and its further enhanced by IL-4. J. Immunol. 166:2001;633-641.
23. + T cell polarisation in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells. J. Exp. Med. 198:2003;201-209.
24. Golumbek P.T., Lazenby A.J., Levitsky H.I., Jaffee L.M., Karasuyama H., Baker M., Pardoll D.M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:1991;713-716.
25. Gorelik L., Constant S.L., Flavell R.A. Mechanisms of transforming growth factor-β-induced inhibition of T helper type I differentiation. J. Exp. Med. 195:2002;1499-1505.
26. Green S.J., Crawford R.M., Hockmeyer J.T., Meltzer M.S., Nacy C.A. Leishmania major amastigotes initiate the L-arginine dependent killing mechanism in IFN-γ-stimulated macrophages by induction of TNF-α J. Immunol. 145:1990;4290-4297.
27. Groux H., Cottrez F., Rouleau M., Mauze S., Antonenko S., Hurst S., McNeil T., Bigler M., Roncarolo M.G., Coffman R.L. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen presenting cells. J. Immunol. 162:1999;1723-1729.
28. Guéry J.-C., Galbiati F., Smiroldo S., Adorini L. Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and β2-microglobulin-deficient BALB/c mice. J. Exp. Med. 183:1996;485-497.
29. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., Johnson L.L., Swain S.L., Lund F.E. Reciprocal regulation of polarised cytokine production by effector B and T cells. Nat. Immunol. 1:2000;475-482.
30. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine leishmaniasis. J. Exp. Med. 169:1989;59-72.
31. Heinzel F.P., Rerko R.M., Hatam F., Locksley R.M. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J. Immunol. 150:1993;3924-3931.
32. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., Gately M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1993;1505-1509.
33. Heinzel F.P., Rerko R.M., Ahmed F., Pearlman E. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J. Immunol. 155:1995;730-739.
34. Held W., Shakhov A.N., Waanders G., Scarpellino L., Luethy R., Kraehenbuhl J.P., MacDonald H.R., Acha-Orbea H. An exogenous mouse mammary tumor virus with properties of Mls-1a (mtv-7). J. Exp. Med. 175:1992;1623-1633.
35. Hilton D.J., Zhang J.-G., Metcalf D., Alexander W.S., Nicola N.A., Wilson T.A. Cloning and characterization of a binding subunit of the interleukin-13 receptor that is also a component of the interleukin-4 receptor. Proc. Natl. Acad. Sci. USA. 93:1996;497-501.
36. + T cells resulting in a state of unresponsiveness to IL-12. J. Immunol. 161:1998;656-661.
37. Himmelrich H., Launois P., Maillard I., Biedermann T., Tacchini-Cottier F., Locksley R.M., Röcken M., Louis J.A. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J. Immunol. 164:2000;4819-4825.
38. Hochrein H., O'Keefe M., Luft T., Vandenabeele S., Grumont R.J., Maraskovsky E., Shortman K. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J. Exp. Med. 192:2000;823-833.
39. + T helper cell phenotype development in a T cell receptor-αβ-transgenic model. J. Exp. Med. 182:1995;1579-1584.
40. Huang F.P., Xu D., Esfandiari E.O., Sands W., Wei X.Q., Liew F.Y. Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses and enhanced nitric oxide production. J. Immunol. 1998;4143-4147.
41. + cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 91:1994;4285-4289.
42. Julia V., Rassoulzadegan M., Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science. 274:1996;421-423.
43. Kalinski P., Smits H.H., Schuitemaker J.H., Vieira P.L., van Eijk M., de Jong E.C., Wierenga E.A., Kapsenberg L.M. IL-4 is a mediator of IL-12p/70 induction by human Th2 cells: reversal of polarised Th2 phenotype by dendritic cells. J. Immunol. 165:2000;1877-1881.
44. Kamanaka M., Yu P., Yasui T., Yoshida K., Kawabe T., Horii T., Kishimoto T., Kikutani H. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity. 4:1996;275-281.
45. Kamogawa Y., Minasi L.-A., Carding S.R., Bottomly K., Flavell R.A. The relationship of IL-4- and IFN-γ-producing T cells studied by lineage ablation of IL-4 producing cells. Cell. 75:1993;985-995.
46. Kane M.M., Mosser D.M. The role of IL-10 in promoting disease progression in Leishmaniasis. J. Immunol. 166:2001;1141-1147.
47. Kopf M., Brombacher F., Kölher G., Kienzle G., Widmann K.-H., Lefrang K., Humborg C., Ledermann B., Solbach W. IL-4 deficient Balb/c mice resist infection with Leishmania major. J. Exp. Med. 184:1996;1127-1136.
48. Kropf P., Etges R., Schopf L., Chung C., Sypek J., Muller I. Characterization of T-cell mediated responses in nonhealing and healing Leishmania major infections in the absence of endogenous IL-4. J. Immunol. 159:1997;3434-3443.
49. Kropf P., Schopf L.R., Chung C.L., Xu D., Liew F.Y., Sypek J.P., Müller I. Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during Leishmania major infection. Eur. J. Immunol. 29:1999;3621-3628.
50. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimumatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
51. -. Eur. J. Immunol. 25:1995;3298-3307.
52. + T cells in BALB/c mice infected with Leishmania major instructs Th2 cell development and susceptibility to infection. Immunity. 6:1997;541-549.
53. Launois P., Swihart K., Milon G., Louis J.A. Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness. J. Immunol. 158:1997;3317-3324.
54. + T cells in resistant mice treated once with anti-IL-12 or IFN-γ antibodies at the onset of infection with Leishmania major instructs Th2 cell development, resulting in nonhealing lesions. J. Immunol. 168:2002;4628-4635.
55. Letterio J.J., Roberts A.B. Regulation of immune response by TGF-β Annu. Rev. Immunol. 16:1998;137-161.
56. Li J., Hunter C.A., Farell J.P. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J. Immunol. 162:1999;974-979.
57. Liew F.Y., Millott S., Li Y., Lelchuck R., Chan W.L., Ziltener H. Macrophage activation by interferon-γ from host-protective T cells is inhibited by interleukin (IL) 3 and IL4 produced by disease-promoting T cells in leishmaniasis. Eur. J. Immunol. 19:1989;1227-1232.
58. Liew F.Y., Millott S., Parkinson C., Palmer R.M., Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144:1990;4794-4797.
59. Locksley R.M., Heinzel F.P., Sadick M.D., Holaday B.J., Gardner K.D. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T cell subset. Ann. Inst. Pasteur/Immunol. 138:1987;744-749.
60. Ma X., Chow J.M., Gri G., Carra G., Gerosa F., Wolf S.F., Dzialo R., Trinchieri G. The interleukin 12 p40 gene promoter is primed by interferon-γ in monocytic cells. J. Exp. Med. 183:1996;147-157.
61. Maillard I., Erny K., Acha-Orbea H., Diggelmann H. A Vβ4-specific superantigen encoded by a new exogenous mouse mammary tumor virus. Eur. J. Immunol. 26:1996;1000-1006.
62. + T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Eur. J. Immunol. 31:2001;1288-1296.
63. Matthews D.J., Emson C.L., McKenzie G.J., Jolin H.E., Blackwell J.M., McKenzie A.N.J. IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 164:2000;1458-1462.
64. Mattner F., Magram J., Ferrante J., Launois P., Di Padova K., Behin R., Gately M.K., Louis J.A., Alber G. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26:1996;1553-1559.
65. Mauël J., Betz-Corradin S., Buchmüller Rouiller Y. Nitrogen and oxygen metabolites and the killing of Leishmania by activated murine macrophages. Res. Immunol. 142:1991;577-580.
66. + T helper type 1 cell responses to Candida albicans. J. Exp. Med. 187:1998;307-317.
67. Mitchell G.F., Curtis J.M., Scollay R.G., Handman E. Resistance and abrogation of resistance to cutaneous leishmaniasis in reconstituted BALB/c mice. Aust. J. Exp. Biol. Med. Sci. 59:1981;539-544.
68. Mock B., Blackwell J., Hilgers J., Potter M., Nacy C. Genetic control of Leishmania major infection in congenic, recombinant inbred and F2 populations of mice. Eur. J. Immunogenet. 20:1993;335-348.
69. Monteforte G.M., Takeda K., Rodriguez-Sosa M., Akira S., David J.R., Satoskar A.R. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J. Immunol. 164:2000;5890-5893.
70. Moser M., Murphy K.M. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 1:2000;199-205.
71. Mosmann T.R., Coffman R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:1989;145-173.
72. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., Waldmann R., Locksley R.M., Glaichenhaus N. Expression cloning of a protective Leishmania antigen. Science. 268:1995;563-566.
73. Müller I., Fruth U., Louis J.A. Immunobiology of experimental leishmaniasis. Med. Microbiol. Immunol. 181:1992;1-12.
74. Nishikomori R., Gurunathan S., Nishikimori K., Strober W. BALB/c mice bearing a transgenic IL-12 receptor β2 gene exhibit a non healing phenotype to Leishmania major infection despite intact IL-12 signaling. J. Immunol. 166:2001;6776-6783.
75. Noben-Trauth N., Kropf P., Muller I. Susceptibility to Leishmania major infection in IL-4 deficient mice. Science. 271:1996;987-990.
76. Noben-Trauth N., Paul W.E., Sacks D.L. IL-4- and IL-4 receptor deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J. Immunol. 162:1999;6132-6140.
77. Noben-Trauth N., Lira R., Nagase H., Paul W.E., Sacks D.L. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170:2003;5152-5158.
78. O'Shea J.J., Paul W.E. Regulation of Th1 differentiation-controlling the controllers. Nat. Immunol. 3:2002;506-508.
79. Oppmann B., Lesley R., Bloom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., Zonin F., Vaisberg E., Churakova T., Liu M., Gorman D., Wagner J., Zurawski S., Liu Y., Abrams J.S., Moore K.W., Rennick D., de Waal-Malefyt R., Hannum C., Bazan J.F., Kastelein R.A. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities as well as distinct from IL-12. Immunity. 13:2000;715-725.
80. Pfeiffer C., Stein J., Southwood S., Ketelaar H., Sette A., Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J. Exp. Med. 181:1995;1569-1574.
81. + T cells. Immunity. 16:2002;779-790.
82. Pingel S., Launois P., Fowell D.J., Turck C.W., Southwood S., Sette A., Glaichenhaus N., Louis J.A., Locksley R.M. Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope. J. Exp. Med. 189:1999;1111-1120.
83. Presky D.H., Yang H., Minetti L.J., Chu A.O., Nabavi N., Wu C.-Y., Gately M., Gübler U. A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA. 93:1996;14002-14007.
84. Radu D.L., Noben-Trauth N., Hu-Li J., Paul W.E., Bona C.A. A targeted mutation in the IL4Ralpha gene protects mice against autoimmune diabetes. Proc. Natl. Acad. Sci. USA. 97:2000;12700-12704.
85. Ramsdell F., Seaman M., Miller R., Picha K., Kennedy M., Lynch D. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int. Immunol. 6:1994;1545-1553.
86. + T cells during initiation of infection. J. Exp. Med. 179:1994;447-456.
87. Roberts M., Mock B.A., Blackwell J.M. Mapping of genes controlling Leishmania major infection in CXS recombinant inbred mice. Eur. J. Immunogenet. 20:1993;349-362.
88. Robinson D.S., O'Garra A. Further checkpoints in Th1 development. Immunity. 16:2002;755-758.
89. Robinson D., Shibuya K., Mui A., Zonin F., Murphy E., Sana T., Hartley S.B., Menon S., Kastelein R., Bazan F., O'Garra A. IGIF does not drive Th1 development but synergies with IL-12 for IFN-γ production and activates IRAK and NF-κB. Immunity. 7:1997;571-581.
90. + T cells producing IL-2 and IL-4. J. Immunol. 148:1992;1031-1036.
91. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:2002;845-858.
92. Sadick M.D., Heinzel F.P., Holaday B.J., Pu R.T., Dawkins R.S., Locksley R.M. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon-γ independent mechanism. J. Exp. Med. 171:1990;115-127.
93. Sadlack B., Kuhn R., Schorle H., Rajewsky K., Muller W., Horak I. Development and proliferation of lymphocytes in mice deficient for both interleukin-2 and -4. Eur. J. Immunol. 24:1994;281-284.
94. Salerno A., Dieli F., Sireci G., Bellavia A., Ashershon G.L. Interleukin-4 is a critical cytokine in contact sensitivity. Immunology. 84:1995;404-409.
95. Satoskar A.R., Okano M., Connaughton S., Raisanen-Sokolwski A., David J.R., Labow M.A. Enhanced Th2-like responses in IL-1 type 1 receptor-deficient mice. Eur. J. Immunol. 28:1998;2066-2074.
96. Scharton-Kersten T., Afonso L.C.C., Wysocka M., Trinchieri G., Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154:1995;5320-5330.
97. Schorle H., Holtschke T., Hunig T., Schimpl A., Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature. 352:1991;621-624.
98. Schuler T., Qin Z., Ibne S., Noben-Trauth N., Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin-4 deficient mice. J. Exp. Med. 189:1999;803-810.
99. Scott P.A. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147:1991;3149-3155.
100. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 168:1988;1675-1684.
101. Seder R.A., Germain R.N., Linsley P.S., Paul W.E. CD28-mediated costimulation of interleukin 2(IL-2) production plays a critical role in T cell priming for IL-4 and interferon γ production. J. Exp. Med. 179:1994;299-304.
102. + suppressor T cells: more question than answers. Nat. Rev. Immunol. 2:2002;389-400.
103. Sinigaglia F., D'Ambrosio D., Panina-Bordignon P., Rogge L. Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effector function. Immunol. Rev. 170:1999;65-72.
104. Smith K.A. Interleukin-2: inception, impact and implications. Science. 240:1988;1169-1176.
105. + T cell mediated cytotoxicity. J. Immunol. 152:1994;1127-1133.
106. von Stebut E., Ehrchen J., Belkaid Y., Lopez kostka S., Mölle K., Knop J., Sunderkétter C., Udey M.C. Interleukin 1α promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J. Exp. Med. 198:2003;191-199.
107. Stenger S., Thüring H., Röllinghoff M., Bogdan C. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J. Exp. Med. 180:1994;783-793.
108. Stetson D.B., Mohrs M., Mallet-Designe V., Teyton L., Locksley R.M. Rapid expansion and IL-4 expression by Leishmania-specific naive helper T cells in vivo. Immunity. 17:2002;191-200.
109. Swain S.L., Weinberg A.D., English M., Huston G. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145:1990;3796-3806.
110. + T cell response. J. Exp. Med. 181:1995;961-971.
111. Sypek J.P., Chung C.L., Mayor S.E.H., Subramanyam S.J., Goldman S.J., Sieburth D.S., Wolf S.F., Schaub R.G. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1993;1797-1802.
112. Szabo S.J., Jacobson N.G., Dighe A.S., Gübler U., Murphy K.M. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity. 2:1995;665-675.
113. Szabo S.J., Sullivan B.M., Stemmann C., Satoskar A.R., Sleckman B.P., Glimcher L.H. Distinct effects of T-bet in Th1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science. 295:2002;338-342.
114. Tepper R.I., Pattengale P.K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57:1989;503-512.
115. - T cell subsets to express IL-18 receptor and produce IFN-γ in response to IL-18. J. Immunol. 160:1998;3759-3765.
116. Traidl C., Jugert F., Krieg T., Merk H., Hunzelmann N. Inhibition of allergic contact dermatitis to DNCB but not oxazolone in interleukin-4- deficient mice. J. Invest. Dermatol. 112:1999;476-482.
117. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:1995;251-276.
118. Vieira L.Q., Hondowicz B.D., Afonso L.C.C., Wysocka M., Trinchieri G., Scott P. Infection with Leishmania major induces interleukin-12 production in vivo. Immunol. Lett. 40:1994;157-161.
119. + effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major. J. Exp. Med. 179:1994;1367-1371.
120. Wolf S.F., Temple P.A., Kobayashi M., Young D., Dicig M., Lowe L., Dzialo R., Fitz L., Ferenz C., Hewick R.M. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biological effect on T and natural killer cells. J. Immunol. 146:1991;3074-3081.
121. + regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection and colitis in mice. J. Immunol. 170:2003;394-399.
122. Yokozeki H., Ghoreishi M., Takagawa S., Takayama K., Satoh T., Katayama I., Takeda K., Akira S., Nishioka K. Signal transducer and activator of transcription 6 is essential in induction of contact hypersensitivity. J. Exp. Med. 191:2000;995-1004.
123. Yoshida H., Hamano S., Senaldi G., Covey T., Faggioni R., Mu S., Xia M., Wakeman A.C., Nishina H., Potter J., Saris C.J., Mak T.W. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity. 15:2001;569-578.